PHA-848125 is a small molecule inhibitor that has been developed for use in cancer treatment. The drug works to block the activity of cyclin-dependent kinases (CDKs), enzymes that play a major role in regulating the cell cycle. This article will provide an overview of PHA-848125, including its chemical properties, health benefits, potential effects, mechanism of action, safety, side effects, and dosing information.
Chemical Properties: Chemical name: 6-( Cyclopropylmethoxy)-7-[(3R)-3-methyl-4-(morpholin-4-yl)-pyrrolidin-1-yl]-9H-purin-2-amine Molecular formula: C19H26N6O2 Formula weight: 362.44 g/mol CAS No: 802539-81-7
Top ten Google Keywords:
Synonyms: PHA848125 PHA848125A PHA 848125 802539-81-7
Health Benefits: PHA-848125 is a promising drug that has shown great potential in treating various forms of cancer. The drug works by inhibiting the activity of CDKs, which are enzymes that regulate cell cycle progression. The dysregulation of CDKs has been linked to the growth and progression of certain cancers. PHA-848125 can act as a potential inhibitor to CDKs, allowing for the possibility of preventing or slowing the growth of tumors.
Potential Effects: There is evidence to suggest that PHA-848125 can be effective in the treatment of various cancers, including ovarian cancer, leukemia, and colon cancer. The drug has exhibited potent antitumor activities in human tumor models. PHA-848125 works by inhibiting CDKs, which prevents the growth and division of cancer cells. Inhibition of CDKs can also help to overcome drug resistance, making this drug particularly useful for patients who have not responded well to other cancer treatments.
Product Mechanism: PHA-848125 works by blocking the activity of CDKs enzymes that are essential for cell cycle progression. CDKs control cell cycle progression by regulating the activity of proteins involved in the cell cycle, ensuring that the cell progresses through each stage of the cycle in a controlled manner. PHA-848125 inhibits the activity of CDKs by binding tightly to the ATP-binding site, which reduces the phosphorylation of downstream targets and ultimately results in cell death.
Safety: PHA-848125 has undergone extensive safety testing in preclinical trials, and the drug has demonstrated a relatively safe toxicity profile.
Side Effects: The side effects of PHA-848125 may include:
Dosing Information: The dosing of PHA-848125 may vary depending on the patient's condition, weight, and other factors. In general, the drug is administered intravenously every 3-4 weeks. The recommended dosage of PHA-848125 typically ranges from 10 mg/m² to 30 mg/m².
Conclusion: PHA-848125 is a promising small molecule inhibitor that has shown potential for the treatment of various cancers. This drug works by inhibiting CDKs, preventing the growth and proliferation of cancer cells. While further clinical studies are needed, this drug has the potential to become a useful treatment option for patients with cancer. Dosing of this drug should be closely monitored to ensure optimal effectiveness and minimal side effects for each individual patient. Additionally, administering the drug under the care of a qualified healthcare provider can provide the most effective treatment plan while monitoring any adverse reactions that may occur.
